Halozyme Therapeutics Inc (FRA:RV7)
€ 45.9 0.41 (0.9%) Market Cap: 5.88 Bil Enterprise Value: 6.68 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 85/100

Halozyme Therapeutics Inc at JMP Securities Life Science Conference Transcript

Jun 19, 2019 / 06:30PM GMT
Release Date Price: €6.08
Jason Butler
JMP Securities - Analyst

All right, so we are going to go ahead and get started. Thank you again for joining us this afternoon at the JMP Securities Life Science Conference. The next company we have here to talk to us is Halozyme and the Company's CFO, Laurie Stelzer. So Laurie, thank you for being with us this afternoon.

Laurie Stelzer
Halozyme Therapeutics - SVP & CFO

Thank you, Jason. Thanks for having me.

Jason Butler
JMP Securities - Analyst

Let me add my congratulations on the news you had very recently, a couple days ago, that you in the 301 study have had the last event to trigger the primary endpoint analysis. So we will get those data by the end of the year. So, great.

Laurie Stelzer
Halozyme Therapeutics - SVP & CFO

That's correct.

Jason Butler
JMP Securities - Analyst

Maybe if we just start there and if you just want to give us a brief update on that announcement and on the trial progress

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot